



**ANNUAL GENERAL
MEETING PRESENTATION**

NOVEMBER 2017



ZELDA
THERAPEUTICS

ASX:ZLD

www.zeldatherapeutics.com



Disclaimer and Important Notice

Disclaimer

This presentation has been prepared by Zelda Therapeutics Ltd ACN 103 782 378 (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

Corporate Overview



Cash at Bank
A\$7.24M as at
30 September 2017

Market Capitalisation
A\$86.8 million as of
23 November 2017

Total Shares **754,841,934**

Total Options **48,000,000**

- Funds to execute **research programme, new opportunities** and **grow clinical pipeline** of medicinal cannabis therapies.
- A **strong pipeline of activities and good news flow** over last 6 months reflected in share price movements.





Company Overview

Zelda Therapeutics was founded out of the USA to focus on delivering validated medical cannabis therapies to market.

Zelda has years of patient data from Californian based Aunt Zelda's and Chilean based Fundación Daya in a range of diseases that has formed the basis of the current pipeline and clinical trials.

Access to USA & Chilean patient data

Existing patient data demonstrates clinical efficacy of Zelda's proprietary formulations in a range of diseases.

Advancement straight to clinical trials

Ability to advance straight to clinical trials using this patient data.

Creating data packs for licensing deals & market launch

Clinical trials to create comprehensive data packs for licensing deals with pharmaceutical and biotech companies.

Board & Management Team



Harry Karelis
Founder & Executive
Chairman

Harry is a co-founder of Jindalee Partners and has in excess of 25 years diversified experience in the financial services sector including specialist med-tech private equity investing

Mara Gordon
Founder &
Director

Mara is the co-founder of Aunt Zelda's and Zelda Therapeutics. She specialises in the development of cannabis extract treatment protocols for seriously ill patients in California

Jason Peterson
Founder &
Director

Jason is a Director, major shareholder and Head of Corporate at boutique stock broking and investment banking firm, CPS Capital. He has more than 21 years of experience in the financial advisory sector

Dr Stewart Washer
Founder &
Director

Stewart has 25 years of CEO and Board experience in medical/biotech. He is currently Chairman of Orthocell Ltd and Director of Cynata Ltd.

Medical Advisory Board



Prof. Manuel Guzman

Full Professor of Biochemistry and Molecular Biology at Madrid's Complutense University and expert on the molecular mechanisms of action and role of cannabinoids in controlling cell generation and death



Dr Cristina Sanchez

Assistant Professor at Complutense University, Madrid Spain. Specialist in the area of lipid signaling, including cannabinoids in an oncology setting



Dr Joe Goldstrich

Distinguished clinical career in preventive cardiology and nutrition spanning over 40 years. He has evaluated over 3,500 patients in the US using cannabis as a fundamental medicine in the management of a variety of medical conditions



Dr Noah Federman

Highly respected paediatric clinical and research oncologist. Currently, Director of the Paediatric Bone and Soft Tissue Sarcoma Program at University of California, part of the prestigious UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Centre

Cannabis 101



- ✓ Cannabis contains over **100 different phyto-cannabinoids** (including the well-known THC & CBD).
- ✓ Cannabinoids **bind to natural receptors in the body** within the endocannabinoid system that are present in the nervous system & throughout the immune system.
- ✓ **Wide range of therapeutic effects** from pain control to anti-inflammatory activity with different ratios of key cannabinoids.



- ✓ Cannabis is a **very safe drug** & has been widely used by people for centuries.
- ✓ Proven treatment, effective for conditions including: **chronic pain, nerve pain, chemotherapy-induced nausea** and **MS Spasticity**
- ✓ National Academy of Sciences and Medicine reviewed some 100,000 studies on preclinical and clinical trial data in these areas



- ✓ Cannabis also shows **real promise in many other areas** including epilepsy, insomnia, anxiety and autism where patients have been treated successfully in the US, Canada & other countries where cannabis is legal.
- ✓ **.More clinical evidence is required** before these become accepted medicines by mainstream doctors.

This is where Zelda is focused to complete clinical studies in areas such as Insomnia and Autism, where there is strong anecdotal evidence

Targeted Areas in Large Patient Markets

- ✓ **Breast** – over 1.7m patients in 2012 [Source: World Cancer Research Fund]
- ✓ **Pancreatic** – 12th most common cancer globally [Source: Pancreatic Cancer World Research Fund].
- ✓ **Glioblastoma (brain)** – 15% of all primary brain tumours [Source: American Brain Tumour Association].



Insomnia affects approx. **35% of adults** [Source: GlobalData].

Estimated **230,000 people** have Autism in Australia [Source: Autism Society]





Pre-clinical

Breast Cancer Research



Initial results showed **THC-rich oil was significantly more potent than pure THC** and was as potent as Lapatanib in reducing tumour growth.



Zelda's formulations tested *in vitro* on **three breast cancer lines**:

- Hormone Receptor Positive (ER/PR+)
- HER2 Positive
- Triple Negative

Results confirm statistically significant **anti-cancer effect across a range of breast cancer cell types.**




THC-rich




CBD-rich




THC-rich



Hormone Receptor Positive
(ER+/PR+)



HER2 positive



Triple Negative


Pre-clinical

Breast Cancer Research


- Potential for cannabinoid-based therapies to be therapeutically beneficial in breast cancer types including **hormone receptor positive, HER2+ and Triple Negative cancer types.**
- **Zelda's THC-rich formulation** had greater anti-cancer effect than pure synthetic THC, across all cancer subtypes including **Triple Negative breast cancers.**

Breast Cancer | Expanded Research

Cancer Stem Cell-like Cells



Encouraging results led to an **expansion of Zelda's current research programme** with Complutense University to investigate the **effect of cannabinoids on cancer stem cell-like cells.**



Cancer Stem Cell-like Cells are cancer cells found within tumours that are **self-renewing, causing tumour re-growths** [Oxford Stem Cell Institute].



This research could lead to **new treatment regimen for highly resistant tumours.**



Clinical

Autism Trial in Chile



Autism is a **lifelong development disability** characterised by impairments in social communication and interactions

[Source: Autism Spectrum].

- Zelda partnered with Chilean non profit organisation **Fundación Daya** - extensive experience in using medical cannabis to treat patients diagnosed with autism for clinical studies.

Autism | Success in Observation Trial




Sponsored observation autism trial in Chile, demonstrated **successful results for treating core symptoms of autism with medicinal cannabis extracts** that Zelda is planning on taking into clinical trials.



Results were presented at the prestigious 23rd **World Congress of Neurology** in Kyoto, Japan.



Results demonstrate cannabis extracts were **more effective than conventional autism medicines.**



71.4% showed significant improvements in **at least one core symptom** and **66.7%** of treated patients showed significant **general overall improvement.**



Successful results will lead to product registration in Chile and **potentially access to the wider South American market.**



Why Chile?

Clinical Trial Programme in Chile



Chilean legal framework **recognises importance of medicinal cannabis**, allowing production under strict regulatory controls for treatment of medical conditions.



Patients in Chile being treated with medical cannabis through **Fundación Daya**



Cost effective location to conduct clinical trials



Australia's 3rd largest trading partner in Latin American – two-way goods and services trading **totaling \$1.8 billion in 2013-2014**, and over 120 Australian companies active in Chile *[Source: Department of Foreign Affairs]*.



Partnerships in place with major Chilean pharma manufacturing group **Knop Laboratories**, to produce Zelda's medicines for the trials and potentially commercial quantities.



Clinical

Insomnia Trial in Australia



- **Insomnia** affects approximately 35% of adults
[Source: GlobalData].



Current Insomnia treatment

- Benzodiazepines are tranquilisers usually prescribed for anxiety and insomnia.
- Overdoses from these cause almost 3 times more deaths than heroin & methamphetamine combined
[Source: SBS].



Zelda's Insomnia Trials

- Working with clinicians, research organisations and regulatory authorities to obtain ethics approval.
- Planned clinical studies.
- Starting in Q1 2018.

Strategic Partnerships



Access to patient data, formulations and protocols for company's current **pre-clinical activities and clinical activities.**



Strategic partnership with **Chilean non-profit group** who have extensive experience in using medicinal cannabis to treat patients diagnosed with autism. Zelda will leverage their clinical experiences and data to develop clinical trials and conduct research.

Other Strategic Partnerships




Strategic partnership with **Australian Animal Health** company developing a range of medicinal cannabis products for animal markets. Zelda has access to all their animal data for human indications. Options over ~7% of CannPal.




Agreement in place with **Chilean pharmaceutical manufacturing** group to provide high quality supply of Zelda's formulated medicines initially for clinical trials and subsequently for commercial production.

Milestones Achieved Since Listing



Comparative Analysis



Company	Market Capitalisation	Focus
Zelda Therapeutics (ASX:ZLD)	AUD \$86.8m	Research: Insomnia, Cancers, Autism and Skin disorders
AusCann (ASX:AC8)	AUD\$213m	Grow and Research: Chronic and Neuropathic Pain Control
CANN Group (ASX:CAN)	AUD\$286m	Grow
Canopy Growth Corporation (TSX:WEED)	CAD\$3.42bn	Grow & Manufacture: Medical & Recreational
GW Pharmaceuticals (NASDAQ:GWPH)	US\$2.84bn	Research: Sativex (MS spasticity), Epidiolex (childhood epilepsy)

Zelda in The Media

YAHOO! The West Australian

Home Latest News Sport Business Politics Opinion Lifestyle Entertainment Digital Edition Plus

STARTUPS

Pot stock Zelda raises \$6m in placement

Stuart McKinson
Thursday 30 March 2017 2:35PM



Dr Stewart Washer discusses the 'Hindrances in legalising medicinal cannabis' on the Health Professional Radio: <http://ow.ly/Ovnp30fqwU5> #zeldatherapeutics #medicalcannabis



DR. STEWART WASHER

HPR

Hindrances in Legalizing Medicinal Cannabis and Stewart Washer

Zelda Therapeutics works on legalizing medicinal cannabis and brings to some of the world's leading researchers and clinicians active in the...

HEALTHPROFESSIONALRADIO.COM.AU

Zelda Therapeutics Share Price Rises 55% on Outstanding Result

PROVIDING INFORMATION AND RESEARCH TO CANNABIS INVESTORS

CANNA INVESTOR

FEBRUARY / MARCH 2017 Magazine

ASX: ZLD



zelda THERAPEUTICS

BRINGING TOGETHER LEADING MEDICINAL CANNABIS RESEARCHERS



+ Aunt Zelda's Top 25 Stocks

Zelda was featured in the West Australian, 16th Sept 2017 issue, 'Firm to test cannabis in bid to find cancer cure': <http://ow.ly/F7nX30ffUpK> #zeldatherapeutics #medicalcannabis



CHECK OUT THESE PRICES

WINE

100% 74%

Firm to test cannabis in bid to find cancer cure | The West Australian

A company spearheading the use of medicinal cannabis is about to start laboratory tests on its patented compounds as a possible...

PRESSREADER.COM

Zelda's Chairman, Harry Karelis was featured in Money Magazine: <http://ow.ly/5yGc30fJcPc> #zeldatherapeutics #medicalcannabis



Medical cannabis investor Harry Karelis | Money Magazine Australia

It's less than a year since cannabis was legalised for medical purposes, and investors haven't let the grass grow beneath their feet....

PRESSREADER.COM


WEST BUSINESS INSIDER

The West Australian

June 2017



Activity Pipeline 2018



Investment Summary

Zelda Therapeutics offers investors exposure to a world-class team at very attractive valuations and with significant valuation drivers over the next 12-18 months.



Significant market opportunity: Medical cannabis is one of the world's fast growing industries with increasing acceptance and regulatory approvals globally



Acceleration straight to clinical efficacy trials through access to Aunt Zelda's patient data and highly defensive products with patent protected formulations



Large target market with focus on large patient populations targeting sleep disorders, eczema and cancers



Clear path to commercialisation with multiple revenue opportunities to license and receive milestone and royalty payments



Industry recognised board & management team and global partnerships with leading medical cannabis firms and operations spanning entire value chain



Significant progress to date with positive results in breast cancer studies and further trials already commenced




Undervalued compared to other clinical stage biotechs and medical cannabis companies

CONTACT

Dr. Stewart Washer

Executive Director

 **AUSTRALIA** Level 45, 108 St Georges Tce, Perth WA, 6000

 **USA** 575 Highway 1, Bodega Bay, CA, 94923

 +61 418 288 212

 swasher@zeldatherapeutics.com

 www.zeldatherapeutics.com



@ZeldaTherapeutics



@ZLDTherapeutics



Zelda Therapeutics